New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv
MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.
13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston
Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)
Longevity Partnering Forum to be held October 19-20, 2026 in South San Francisco
Longevity and Aging-Related FrailtyThe Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.
New Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published on medRxivThe Company has recently published a new manuscript as a pre-print in medRxiv, detailing post-hoc exploratory analysis from the Company’s Phase 2a randomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated laromestrocel treatment may reduce neuroinflammation in the brain—a core driver of AD pathogenesis, using free water MRI imaging.
This is a preprint and has not yet completed peer review. Laromestrocel is an investigational product and has not been approved by the FDA or any other regulatory agency.
Read the full preprint: https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
Key findings:
- Laromestrocel inhibited the progression of neuroinflammation, with the strongest effects in regions at the core of Alzheimer's pathology, including the left hippocampus (p